Trial Profile
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of PXL065 (DRX-065) Compared to Actos In Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Feb 2020
Price :
$35
*
At a glance
- Drugs Pioglitazone deuterated (Primary) ; Pioglitazone
- Indications Adrenomyeloneuropathy; Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Poxel
- 12 Nov 2019 Results presented in a Poxel media release.
- 12 Nov 2019 According to a Poxel media release, data from this study were presented at the Liver Meeting 2019 hosted by the American Association for the Study of Liver Diseases (AASLD).
- 17 Sep 2019 According to a Poxel media release, data from this study will be presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting, to be held November 8-12, 2019 in Boston, MA.